IRCT2013093012924N1已完成2 期
Study the preventive effect of Carvedilol therapy against Adriamycin-induced acute cardiotoxicity in breast cancer patients by measurement of myocardial deformation index
Vice chancellor for research, Mashhad University of Medical Sciences0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 65 years（—）
- 性别
- Female
入选标准
- •breast cancer patients who are candidate for chemotherapy with adriamycin.
- •Exclusion criteria:
- •documented heart disease; history of radiation or chemotherapy for cancer; metastatic disease; atrial fibrillation; BMI more than 30; creatinin more than 2; EF less than 30%; pulmonary congestion; beta blocker contraindications; insulin dependent diabetes mellitus; major depression; suicide attempt; pregnancy
排除标准
- 未提供
研究者
相似试验
招募中
3 期
Effect of Carvedilol on Reducing Transtosomab Cardiac ComplicationsIRCT20190628044046N1Tehran University of Medical Sciences60
已完成
3 期
Assessment the effect of Carvedilol in preventing Heart failure in breast cancer patients.IRCT2017042433619N1Vice chancellor for research of Baqiyatallah University of Medical Sciences50
招募中
3 期
Evaluation of the effect of carvedilol in patients with gastrointestinal cancerGastrointestinal cancers (Esophageal cancer, Gastric cancer, Pancreatic cancer, Colon cancer).Malignant neoplasm of stomachIRCT20200907048646N1Ardabil University of Medical Sciences60
已完成
2 期
Effect of carvedilol in preventing heart failure following herceptin therapybreast cancer.Malignant neoplasm of breastC50-C50IRCT2014112019840N1Vice chancellor of research of Tehran university of medical scienses100
尚未招募
不适用
S1501 Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III”NeoplasmsKCT0004843ational Cancer Center20